In:
Journal of Orthopaedic Research, Wiley, Vol. 30, No. 9 ( 2012-09), p. 1493-1498
Abstract:
Synovial sarcoma is an aggressive soft tissue sarcoma with only a modest response to conventional cytotoxic agents. In the present study, we evaluated the potential antitumor effects of a novel anti‐angiogenesis agent, pazopanib, against synovial sarcoma cells. We found that pazopanib directly inhibited the growth of synovial sarcoma cells by inducing G1 arrest. Multiplex analyses revealed that the PI3K‐AKT pathway was highly suppressed in pazopanib‐sensitive synovial sarcoma cells. Furthermore, administration of pazopanib highly suppressed the tumor growth in a xenograft model. Taken together, these results suggest pazopanib as a possible agent against synovial sarcoma and may warrant further clinical studies. © 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:1493–1498, 2012
Type of Medium:
Online Resource
ISSN:
0736-0266
,
1554-527X
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2050452-4
Permalink